皇冠正网(www.hg108.vip):Sanofi ends cancer drug trials

皇冠正网www.hg108.vip)是一个开放皇冠正网即时比分、皇冠正网开户的平台。皇冠正网开户平台(www.hg108.vip)提供最新皇冠登录,皇冠正网APP下载包含新皇冠体育正网代理、会员APP。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

免费足球贴士www.hgbbs.vip)是国内最权威的足球赛事报道、预测平台。免费提供赛事直播,免费足球贴士,免费足球推介,免费专家贴士,免费足球推荐,最专业的免费足球贴士网。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。

  • 评论列表:
  •  皇冠网址(www.hg108.vip)
     发布于 2022-09-05 00:04:22  回复
  • But as an exercise in owning up and cleaning up, Venkat, as the CEO is widely known, appears to have made the right calls.你们打几分

添加回复:

◎欢迎参与讨论,请在这里发表您的看法、交流您的观点。